Abstract
Jayson GC et al. remarked in Lancet that nearly 100% of mucinous ovarian cancer cases have Kras mutation as well as a high frequency of Her2 amplification. Using the Abbott PathVysion Her2 DNA Probe Kit and Kras mutant-enriched PCR Kits (FemtoPath®), 21 samples of primary ovarian mucinous cystadenocarcinomas from Taiwanese patients were examined to determine the status of Her2 amplification and Kras mutations. Our results showed the Her2 amplification rates were 33.33%, while the Kras mutation rates were 61.90%. We present here our results in order to enlighten the readership that the ~100% Kras mutant frequency and the high Her2 amplification rate reported by Jayson et al. may be too exaggerated to be applicable into all populations. Additionally, we report another 2 novel Kras mutations (A11V, V14I).
Highlights
We read with great interest the work by Jayson et al in Lancet (Oct. 2014)
The authors presented a comprehensive review of outstanding quality. They remarked that mucinous ovarian carcinoma has a nearly 100% human VKi-ras2 Kirsten rat sarcoma viral oncogene homolog (Kras) mutation as well as a high frequency of human epidermal growth factor receptor 2 (Her2) amplification [1]
Literature reviews revealed that in mucinous ovarian carcinoma, the frequency of Her2 amplification/over-expression is estimated to be between 18 and 35% [2], and the presence of human Kras mutations is 13 to 60% [3,4,5]. This preliminary report aims to enlighten the readership that the ~100% Kras mutant frequency and the high Her2 amplification rate in mucinous ovarian carcinoma may be higher than what has been observed in other studies, including our own
Summary
We read with great interest the work by Jayson et al in Lancet (Oct. 2014). The authors presented a comprehensive review of outstanding quality. Main text We read with great interest the work by Jayson et al in Lancet (Oct. 2014). They remarked that mucinous ovarian carcinoma has a nearly 100% human VKi-ras2 Kirsten rat sarcoma viral oncogene homolog (Kras) mutation as well as a high frequency of human epidermal growth factor receptor 2 (Her2) amplification [1].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
